• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety of Percutaneous Coronary Intervention Without P2Y12 Inhibitor Pretreatment From a Cohort of Unselected Patients.
CONCLUSIONS: In an unselected population admitted for elective PCI or NSTEMI in real-world clinical practice, administration of a P2Y12 inhibitor only after coronary angiography is associated with a low rate of ischemic and bleeding events at 30 days. PMID: 30012889 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - July 18, 2018 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Dual Antithrombotic Therapy with Clopidogrel and Novel Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Real-world Study
ConclusionsIn this long-term study of high-risk and real-world AF-patients with PCI, DT with NOAC and P2Y12 inhibitor (6  months) followed by NOAC monotherapy was safe and effective.
Source: Cardiology and Therapy - June 1, 2018 Category: Cardiology Source Type: research

In-Hospital Bleeding and Utility of a Maintenance Dose of Prasugrel 2.5 mg in High Bleeding Risk Patients With Acute Coronary Syndrome.
CONCLUSIONS: The maintenance dose of adjusted prasugrel 2.5 mg/day seems to be one option in ACS patients at high bleeding risk. PMID: 29695656 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 26, 2018 Category: Cardiology Authors: Ohya M, Shimada T, Osakada K, Kuwayama A, Miura K, Murai R, Amano H, Kubo S, Otsuru S, Habara S, Tada T, Tanaka H, Fuku Y, Katoh H, Goto T, Kadota K Tags: Circ J Source Type: research

Dual Antithrombotic Therapy with Clopidogrel and Novel Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Real-world Study
ConclusionsIn this long-term study of high-risk and real-world AF-patients with PCI, DT with NOAC and P2Y12 inhibitor (6  months) followed by NOAC monotherapy was safe and effective.
Source: Cardiology and Therapy - April 9, 2018 Category: Cardiology Source Type: research

6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
Publication date: Available online 12 March 2018 Source:The Lancet Author(s): Joo-Yong Hahn, Young Bin Song, Ju-Hyeon Oh, Deok-Kyu Cho, Jin Bae Lee, Joon-Hyung Doh, Sang-Hyun Kim, Jin-Ok Jeong, Jang-Ho Bae, Byung-Ok Kim, Jang Hyun Cho, Il-Woo Suh, Doo-il Kim, Hoon-Ki Park, Jong-Seon Park, Woong Gil Choi, Wang Soo Lee, Jihoon Kim, Ki Hong Choi, Taek Kyu Park, Joo Myung Lee, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon Background Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients...
Source: The Lancet - March 13, 2018 Category: General Medicine Source Type: research

A Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients with Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization.
Conclusions -The present study in elderly ACS patients showed no difference in the primary endpoint between reduced-dose prasugrel and standard-dose clopidogrel. However, the study should be interpreted in the light of premature termination of the trial. Clinical Trial Registration -URL: https://clinicaltrials.gov/ Unique Identifier: NCT01777503. PMID: 29459361 [PubMed - as supplied by publisher]
Source: Circulation - February 19, 2018 Category: Cardiology Authors: Savonitto S, Ferri LA, Piatti L, Grosseto D, Piovaccari G, Morici N, Bossi I, Sganzerla P, Tortorella G, Cacucci M, Ferrario M, Murena E, Sibilio G, Tondi S, Toso A, Bongioanni S, Ravera A, Corrada E, Mariani M, Di Ascenzo L, Petronio AS, Cavallini C, Vit Tags: Circulation Source Type: research

Percutaneous coronary intervention without P2Y12 inhibitor pretreatment: A real-life study
Conclusions In an unselected population admitted for elective PCI or NSTEMI in real-life practice, administration of a P2Y12 inhibitor only after coronary angiography is associated with a low rate of ischaemic and bleeding events at 30 days.
Source: Archives of Cardiovascular Diseases Supplements - January 5, 2018 Category: Cardiology Source Type: research

Plasma Metal Concentrations and Incident Coronary Heart Disease in Chinese Adults: The Dongfeng-Tongji Cohort
Conclusions: Our study suggested that incident CHD was positively associated with plasma levels of titanium and arsenic, and inversely associated with selenium. Additional research is needed to confirm these findings in other populations. https://doi.org/10.1289/EHP1521 Received: 22 December 2016 Revised: 17 September 2017 Accepted: 19 September 2017 Published: 19 October 2017 Address correspondence to T. Wu, or A. Pan, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hongkong Rd., Wuhan 430030, Hubei, China. Telephone: +86-27-83692347. Email: wut@mails.tjmu.edu.cn or p...
Source: EHP Research - October 20, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Head ‐to‐head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta‐analysis of randomized controlled trials
ConclusionsAlthough the efficacy was similar between prasugrel and ticagrelor, prasugrel may be associated with a lower risk of bleeding compared with ticagrelor during short‐ to mid‐term follow‐up period after PCI. Further studies are warranted in a larger patient population during longer‐term follow up to validate these findings.
Source: Journal of Interventional Cardiology - August 1, 2017 Category: Cardiology Authors: Ryota Sakurai, Ivana Burazor, Heidi N. Bonneau, Hideaki Kaneda Tags: ORIGINAL INVESTIGATION Source Type: research

Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
CONCLUSION: In this prospective registry, there were no significant differences in the rates of in-hospital MACE or major bleeding after prehospital initiation of UFH, enoxaparin or bivalirudin in patients treated by primary PCI for STEMI. PMID: 27818120 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - November 2, 2016 Category: Cardiology Authors: Auffret V, Leurent G, Boulmier D, Bedossa M, Zabalawi A, Hacot JP, Coudert I, Filippi E, Castellant P, Rialan A, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Le Guellec M, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research

Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy Coronary Interventions
Conclusions— ST reporting by an ACL, a CEC, and LIs is discordant. The assessment of ST is more often detected by direct review of angiograms by an ACL. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00527943.
Source: Circulation: Cardiovascular Interventions - May 8, 2016 Category: Cardiology Authors: Popma, C. J., Sheng, S., Korjian, S., Daaboul, Y., Chi, G., Tricoci, P., Huang, Z., Moliterno, D. J., White, H. D., Van de Werf, F., Harrington, R. A., Wallentin, L., Held, C., Armstrong, P. W., Aylward, P. E., Strony, J., Mahaffey, K. W., Gibson, C. M. Tags: Angiography, Imaging, Percutaneous Coronary Intervention Coronary Interventions Source Type: research

Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention
In conclusion, in our population, F2R IVS-14 PAR1 variability does not affect risk of MACE or bleeding following PCI.
Source: Journal of Thrombosis and Thrombolysis - March 30, 2016 Category: Hematology Source Type: research

Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: One-year outcomes from the GReek AntiPlatelet Registry (GRAPE).
CONCLUSIONS: In real-word ACS/PCI patients, prasugrel offered better antiischemic protection than clopidogrel, while use of both novel agents is accompanied by more frequent bleeding events. This article is protected by copyright. All rights reserved. PMID: 26990959 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 16, 2016 Category: Hematology Authors: Alexopoulos D, Xanthopoulou I, Deftereos S, Hamilos M, Sitafidis G, Kanakakis I, Pentara I, Vavouranakis M, Davlouros P, Hahalis G, Goudevenos J Tags: J Thromb Haemost Source Type: research

Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel.
CONCLUSIONS: In this small, retrospective analysis, the results of loading patients with prasugrel for PCI and switching them to clopidogrel without a loading dose appear to be encouraging. PMID: 26378415 [PubMed - in process]
Source: The Journal of Invasive Cardiology - March 11, 2016 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: One‐year outcomes from the GReek AntiPlatelet Registry (GRAPE)
ConclusionsIn real‐word ACS/PCI patients, prasugrel offered better antiischemic protection than clopidogrel, while use of both novel agents is accompanied by more frequent bleeding events.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 1, 2016 Category: Hematology Authors: D. Alexopoulos, I. Xanthopoulou, S. Deftereos, M. Hamilos, G. Sitafidis, I. Kanakakis, I. Pentara, M. Vavouranakis, P. Davlouros, G. Hahalis, J. Goudevenos Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Pages: 1  2  3  4  5  6  7